Carmelo J. Blanquicett

Carmelo J. Blanquicett

Auto-generated profile, based on publicly available information

Carmelo J. Blanquicett

Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2007 in British Journal of Cancer
Verified
Journal Article
Open access
RFR Fanciullino
R Fanciullino
SGS Giacometti
S Giacometti
CMC Mercier
C Mercier
CAC Aubert
C Aubert
CBC Blanquicett
C Blanquicett
Joseph CiccoliniJoseph Ciccolini
Joseph Ciccolini
Drug resistance is a major cause of treatment failure in cancer chemotherapy, including that with the extensively prescribed antimetabolite, 5-fluorouracil (5-FU). In this study, we tried to reverse 5-FU resistance by using a double-punch strategy: combining 5-FU with a biochemical modulator to improve its tumoural activation and encapsulating both these agents in one same stealth liposome. Experiments carried out in the highly resistant, canonical SW620 human colorectal model showed a up to 80% sensitisation to 5-FU when these cells were treated with our liposomal formulation. Results with this formulation demonstrated 30% higher tumoural drug uptake, better activation with increased active metabolites including critical-5-fluoro-2-deoxyuridine-5-monophosphate, superior inhibition (98%) of tumour thymidylate synthase, and subsequently, higher induction of both early and late apoptosis. Drug monitoring showed that higher and sustained exposure was achieved in rats treated with liposomal formulation. When examined in a xenograft animal model, our dual-agent liposomal formulation caused a 74% reduction in tumour size with a mean doubling in survival time, whereas standard 5-FU failed to exhibit significant antiproliferative activity as well as to increase the lifespan of tumour-bearing mice. Taken collectively, our data suggest that resistance to 5-FU can be overcome through a better control of its intratumoural activation and the use of an encapsulated formulation.

11 May 2022 in Clinical Hematology International
Verified
Journal Article
Open access
PDF file
MSMaría del Pilar Gamarra Samaniego
María del Pilar Gamarra Samaniego
CBCarmelo J. Blanquicett
Carmelo J. Blanquicett
RCRoger V. Araujo Castillo
Roger V. Araujo Castillo
JCJulio C. Chavez
Julio C. Chavez
BGBrady Ernesto Beltrán Garate
Brady Ernesto Beltrán Garate
Background: The incidence of Non-Hodgkin Lymphoma (NHL) is increasing, particularly among older patients who tend to have worse outcomes and can be predisposed to increased toxicities and less treatment tolerance. Therefore, a thorough pre-treatment assessment is essential. A comprehensive geriatric assessment (CGA) can be used to evaluate the older patient considering chemotherapy and is the preferred evaluation tool. However, a formal CGA is laborious, complex and time-consuming. Objectives: To characterize older adults with NHL and determine the CGA variables with the greatest association to frailty in order to propose a more simplified assessment. Methods: We performed a cross-sectional study using data collected from CGAs in NHL patients > 65 years admitted to our oncology service, from September 2015 to August 2017. Our evaluation parameters included: polypharmacy, a screening tool of older people's prescriptions (STOPP), the Lawton scale, Barthel index, Katz index, gait speed, a Timed Up and Go (TUG) test, a Mini-Mental state examination (MMSE), the Yesavage and Gijon scales, a Mini-nutritional assessment (MNA), a Geriatric Syndromes assessment, and a Cumulative Illness Rating Scale-Geriatric (CIRS-G). The formal CGA was comprised of nine domains; frailty was defined as an impairment in > 2 domains. Each parameter was individually compared with frailty, and the results were used to build different multivariate models using logistic regression analyses to obtain the variables with the highest frailty association. Results: A total of 253 patients were included. Their median age was 75.4 years (range 65–92), and 62.1% had > 1 impaired domain, with 39.9% considered frail. Bivariate analysis showed strong associations with age > 85 and all the geriatric parameters except for STOPP. Our final multivariate analysis resulted in 5 domains (the use of > 5 medications, a Lawton < 7, TUG > 20, Yesavage > 5, and the presence of at least one geriatric syndrome) being significantly associated with frailty and performing similarly to a CGA. Conclusion: In our population of older NHL patients, an abbreviated evaluation based of only five domains, polypharmacy, TUG, Lawton scale, Yesavage scale and the presence of at least one geriatric syndrome, had similar performance to a formal CGA in determining frailty.

9 September 2021 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
CBCarmelo J. Blanquicett
Carmelo J. Blanquicett
TRTapasya Raavi
Tapasya Raavi
AMAnna Mirk
Anna Mirk
TJTheodore M. Johnson
Theodore M. Johnson
MJMichael Jaglal
Michael Jaglal
ECEmily J. Cartwright
Emily J. Cartwright

1 June 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
SMSophie Moravec
Sophie Moravec
LBLaura V. Barton
Laura V. Barton
RSRevathy Suresh
Revathy Suresh
LHLaura Hayward
Laura Hayward
TSTara Schmidlen
Tara Schmidlen
JPJennifer Permuth
Jennifer Permuth
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) ranks third in cancer-related deaths. Although national guidelines recommend germline multigene panel testing (MGPT) for all patients with PDAC, only 6%-19% undergo testing, mostly due to under-referral and genetic counselor shortages. We evaluated a coordinator-led and digitally supported workflow designed to increase access to pretest education, improve MGPT uptake, and reduce turnaround time (TAT) for patients newly diagnosed with PDAC at our center. METHODS: Through the Genetic Information for Treatment Decisions (GIFTD) Initiative, a Genetic Risk Education Coordinator (GREC) served as a liaison between providers, genetic counselors, and patients. Subsequently, we partnered with Nest Genomics to develop the GIFTD Partially Automated Nest Copilot (G-PANC), a digital tool that collects cancer history, delivers genetic education, and assesses MGPT interest before coordinator follow-up. Outcomes included genetic education completion, MGPT uptake, and TAT across sequential phases (baseline, GREC-only, and G-PANC [GREC+ Nest Copilot]). RESULTS: Over 1 year, 354 patients with PDAC were invited to access G-PANC; 73% activated accounts, 80% completed education, and 63% expressed MGPT interest. Among those completing education, 86% engaged with the GREC, and 81% consented to testing, including 15 initially uninterested patients. Of the 127 patients tested, 13% had pathogenic variants. Compared with a baseline/traditional workflow, the GREC-only phase was associated with increased MGPT uptake (43% to 80%) and reduced TAT (54 to 30 days). During the subsequent G-PANC phase, testing uptake remained high (77%) and TAT further decreased to 22 days. CONCLUSION: A coordinator-led workflow substantially increased MGPT uptake and reduced TAT. Digital education integration was feasible, maintained high testing rates, and reduced TAT. Prospective evaluation will clarify the independent contributions of digital automation.